Therapeutic Advances for Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is an autosomal inherited neurodegenerative disorder.
• Pathology stems from expanded cytosine-adenine-guanine (CAG) repeats in the huntingtin gene (HTT), leading to mutant huntingtin protein (mHTT).
• Clinical manifestations include motor deficits (chorea), cognitive impairment, and psychiatric disturbances.

Purpose of the Study:

• To review current therapeutic research approaches for Huntington's disease.
• To discuss the potential applications of novel treatment strategies.

Main Methods:

• Review of existing and emerging therapeutic strategies for HD.
• Analysis of approaches targeting the huntingtin gene (HTT) and mutant huntingtin protein (mHTT).
• Exploration of gene editing techniques to reduce CAG repeat expansions.

Main Results:

• Symptomatic treatments targeting various pathways are available and in development.
• Novel approaches focus on directly addressing the genetic and protein-level cause of HD.
• Gene editing offers potential for reducing CAG repeats.

Conclusions:

• Advances in analytical tools and treatment goals are crucial for assessing clinical outcomes.
• Targeting mHTT and the HTT gene represents a promising therapeutic direction.
• Effective HD treatments could benefit other inherited and neurological disorders.